“…The remaining ten studies are shown in Table S2 in the supplementary material with the reasons for exclusion. Of these ten trials, six investigated secukinumab (CLEAR [20], ERASURE [21], FUTURE 1 [22], FIXTURE [21], FUTURE 2 [18], and McInnes et al [23]), and the remaining four studied adalimumab (ADEPT [15], Behrens et al [24], Genovese et al [25], and van Kuijk et al [26]). Three of these trials, CLEAR, ERASURE, and FIXTURE, were then excluded because they included patients with moderate-to-severe psoriasis, of whom only a subgroup had concomitant PsA.…”